NeuroMetrix (NURO) 10-Q 26 Apr 22 2022 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2022	Apr. 25, 2022
Document Information [Line Items]
Substantial Doubt about Going Concern, within One Year [true false]	false
Entity Central Index Key	0001289850
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		7,130,091
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Type	10-Q
Entity Current Reporting Status	Yes
Entity Small Business	true
Entity Interactive Data Current	Yes
Security Exchange Name	NASDAQ
Trading Symbol	NURO
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-33351
Entity Registrant Name	NEUROMETRIX, INC.
Entity Incorporation, State or Country Code	DE
Entity Address, Postal Zip Code	01801
Local Phone Number	890-9989
Entity Filer Category	Non-accelerated Filer
Entity Tax Identification Number	04-3308180
Entity Address, Address Line One	4B Gill Street
Entity Address, City or Town	Woburn
Entity Address, State or Province	MA
City Area Code	781
Title of 12(b) Security	Common Stock, $0.0001 par value per share

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 23,769,380	$ 22,572,104
Accounts receivable, net	683,319	310,818
Inventories	711,936	706,553
Prepaid expenses and other current assets	422,616	598,384
Total current assets	25,587,251	24,187,859
Fixed assets, net	184,346	198,703
Operating Lease, Right-of-Use Asset	450,374	475,230
Other long-term assets	26,400	26,400
Total assets	26,248,371	24,888,192
Current liabilities:
Accounts payable	360,855	284,036
Accrued expenses and compensation	1,207,008	814,155
Accrued Sales Return provisions	11,000	39,000
Operating Lease, Liability, Current	148,391	228,506
Total current liabilities	1,727,254	1,365,697
Operating Lease, Liability, Noncurrent	283,209	306,709
Total liabilities	2,010,463	1,672,406
Commitments and contingencies
Stockholders’ equity:
Common Stock, Value, Issued	701	669
Additional paid-in capital	224,359,025	222,378,373
Accumulated deficit	(200,121,819)	(199,163,257)
Total stockholders’ equity	24,237,908	23,215,786
Total liabilities and stockholders’ equity	$ 26,248,371	$ 24,888,192
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	25,000,000	25,000,000
Common Stock, Shares, Issued	7,006,055	6,694,296
Common Stock, Shares, Outstanding	7,006,055	6,694,296
Convertible preferred stock
Stockholders’ equity:
Preferred stock	$ 1	$ 1
Preferred Non-Convertible Stock
Stockholders’ equity:
Preferred stock	$ 0	$ 0

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue from Contract with Customer, Including Assessed Tax	$ 2,302,391	$ 2,155,472
Other Nonoperating Income	3,428	412
Net loss	$ (958,562)	$ (59,783)
Earnings Per Share, Diluted	$ (0.14)	$ (0.02)
Earnings Per Share, Basic	$ (0.14)	$ (0.02)
Loss from operations	$ (961,990)	$ (60,195)
Operating expenses:
Research and development	710,577	233,277
Sales and marketing	858,839	393,825
General and administrative	1,186,091	1,012,276
Total operating expenses	2,755,507	1,639,378
Gross profit	1,793,517	1,579,183
Cost of revenues	$ 508,874	$ 576,289

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Cash Flows [Abstract]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ (958,562)	$ (59,783)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	12,877	22,182
Stock-based compensation	37,632	68,863
IdleFacilityImpairmentCharge	0	126,748
Gain (Loss) on Disposition of Property Plant Equipment	6,875	0
Changes in operating assets and liabilities:
Accounts receivable	(372,501)	(143,392)
Inventories	(5,383)	71,656
Prepaid expenses and other current and long-term assets	37,009	(16,043)
Accounts payable	76,819	238,932
Accrued expenses and compensation	452,853	(332,953)
Increase (Decrease) in Accrued Product Returns	(28,000)	(10,000)
Net Cash Provided by (Used in) Operating Activities	(740,381)	(33,790)
Cash flows from investing activities:
Purchases of fixed assets	(5,395)	(21,453)
Net Cash Provided by (Used in) Investing Activities	(5,395)	(21,453)
Cash flows from financing activities:
Net proceeds from issuance of stock and warrants	1,943,052	4,197
Payments of Stock Issuance Costs	0	(30,000)
Net Cash Provided by (Used in) Financing Activities	1,943,052	(25,803)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	1,197,276	(81,046)
Cash and cash equivalents, end of period	23,769,380
Supplemental disclosure of cash flow information:
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 23,769,380	$ 5,145,167

Equity Rollforward Statement

Equity Rollforward Statement - USD ($)	Total	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Common Stock [Member]	Preferred StockConvertible Preferred Stock [Member]
Stockholders' Equity Attributable to Parent	$ 5,247,775	$ 202,129,194	$ (196,881,800)	$ 380	$ 1
Shares, Outstanding				3,807,555	200
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	68,863	68,863
Stock Issued During Period, Value, Employee Stock Purchase Plan	4,197	4,196
Net Income (Loss) Attributable to Parent	(59,783)		(59,783)
Stockholders' Equity Attributable to Parent	5,261,052	202,202,253	(196,941,583)	$ 381	$ 1
Shares, Outstanding				3,809,963	200
Stockholders' Equity Attributable to Parent	23,215,786	222,378,373	(199,163,257)	$ 669	$ 1
Shares, Outstanding				6,664,296	200
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	37,632	37,632
Stock Issued During Period, Value, New Issues	1,943,052	1,943,023		$ 29
Stock Issued During Period, Value, Restricted Stock Award, Gross	0	(3)		$ 3
Stock Issued During Period, Shares, Restricted Stock Award, Gross				1,759
Net Income (Loss) Attributable to Parent	(958,562)		(958,562)
Stockholders' Equity Attributable to Parent	$ 24,237,908	$ 224,359,025	$ (200,121,819)	$ 701	$ 1
Shares, Outstanding				6,958,555	200

Business and Basis of Presentat

Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Our Business-An Overview NeuroMetrix, Inc. (the "Company" or "NeuroMetrix") develops and commercializes health care products that utilize non-invasive neurostimulation. Revenues are derived from the sale of medical devices and after-market consumable products and accessories. The Company’s products are sold in the United States and select overseas markets. They are cleared by the U.S. Food and Drug Administration ("FDA") and regulators in foreign jurisdictions where appropriate. The Company has two primary products. DPNCheck® is a point-of-care test for diabetic peripheral neuropathy, which is the most common long-term complication of Type 2 diabetes. Quell is an app-enabled, over-the-counter wearable device for chronic pain. The Company held cash and cash equivalents of $23.8 million as of March 31, 2022. The Company has a history of operating losses and has financed its operations primarily from sales of equity, from collaboration milestone payments, and from sales of its products. The Company believes that its present balance of cash resources coupled with cash inflows from product sales will enable the Company to fund its operations for at least the next twelve months from the date of issuance of the financial statements. Actual cash requirements could differ from management's projections for many reasons. These include the effects of the Covid-19 pandemic on sales, procurement of production materials, and maintenance of critical staffing. They could also include changes the Company may make to its business strategy that affect operating expenses, regulatory developments, changes to research and development spending plans; and other items affecting the Company's projected uses of cash. Unaudited Interim Financial Statements The accompanying unaudited balance sheet as of March 31, 2022, unaudited statements of operations, changes in stockholders' equity for the quarters ended March 31, 2022 and 2021 and cash flows for the quarters ended March 31, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying balance sheet as of December 31, 2021 does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair presentation of the Company’s financial position and operating results. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on January 28, 2022 (File No. 001-33351). Revenues Revenues include product sales, net of estimated returns. Revenue is measured as the amount of consideration the Company expects to receive in exchange for product transferred. Revenue is recognized when contractual performance obligations have been satisfied and control of the product has been transferred to the customer. In most cases, the Company has a single product delivery performance obligation. Accrued product returns are estimated based on historical data and evaluation of current information. Accounts receivable are recorded at the amount the Company expects to collect, net of the allowance for doubtful accounts receivable. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses based on customer past payment history, product usage activity, and recent communications with the customer. Individual customer balances which are over 90 days past due are reviewed individually for collectability and written-off when recovery is not probable. Allowance for doubtful accounts was $25,000 as of March 31, 2022 and December 31, 2021. One customer accounted for 43% and 36% of total revenues in the quarters ended March 31, 2022 and 2021, respectively. Three customers accounted for 55% and two customers accounted for 35% of accounts receivable as of March 31, 2022 and December 31, 2021, respectively. Stock-based Compensation Total compensation cost related to non-vested awards not yet recognized at March 31, 2022 was $93,991. The total compensation costs are expected to be recognized over a weighted-average period of 3.4 years. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.

Comprehensive Loss

Comprehensive Loss	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Comprehensive Loss	Comprehensive Loss For the quarters ended March 31, 2022 and 2021, the Company had no components of other comprehensive loss other than net loss itself.

Net Loss Per Common Share

Net Loss Per Common Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Common Share	3. Net Loss Per Common Share Basic and dilutive net loss per common share were as follows: Quarters Ended March 31, 2022 2021 Net loss applicable to common stockholders $ (958,562) $ (59,783) Weighted average number of common shares outstanding, basic 6,893,164 3,796,120 Weighted average number of common shares outstanding, dilutive 6,893,164 3,796,120 Net loss per common share applicable to common stockholders, basic and diluted $ (0.14) $ (0.02) Shares underlying the following potentially dilutive weighted average number of common stock equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive for each of the periods presented: Quarters Ended March 31, 2022 2021 Options 510,256 368,510 Convertible preferred stock 62 62 Total 510,318 368,572
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Quarters Ended March 31, 2022 2021 Net loss applicable to common stockholders $ (958,562) $ (59,783) Weighted average number of common shares outstanding, basic 6,893,164 3,796,120 Weighted average number of common shares outstanding, dilutive 6,893,164 3,796,120 Net loss per common share applicable to common stockholders, basic and diluted $ (0.14) $ (0.02)

Inventories

Inventories	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: March 31, 2022 December 31, 2021 Purchased components $ 413,653 $ 422,093 Finished goods 298,283 284,460 $ 711,936 $ 706,553

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses and Compensation Accrued expenses and compensation consist of the following: March 31, 2022 December 31, 2021 Professional services $ 156,000 $ 109,000 Compensation 825,698 440,474 Warranty 24,800 28,400 Leasehold $ — $ 60,000 Sales Tax $ 139,507 $ 108,788 Other 61,003 67,493 $ 1,207,008 $ 814,155

Leases Leases (Notes)

Leases Leases (Notes)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Lessee, Operating Leases [Text Block]	6. Operating Leases The Company's lease on its Woburn, Massachusetts corporate office and manufacturing facilities extends through September 2025 with a monthly base rent of $13,846 and a 5-year extension option. Future minimum lease payments under non-cancellable operating leases as of March 31, 2022 are as follows: 2022 124,339 2023 165,785 2024 165,785 2025 117,431 Total minimum lease payments $ 573,340 Discount rate, 15% $ 141,740 Lease obligation, current portion 148,391 Lease obligation, net of current portion 283,209 $ 573,340 The Company's lease on its former corporate office in Waltham, Massachusetts expired in February 2022. During the first quarter of 2021, the Company recorded an impairment charge of $126,748 on that idle facility which was being offered for sublet. In the first quarter of 2022, a $60,000 reduction in rent expense was recorded upon return of the facility to the lessor. The letter of credit issued by a bank in favor of the Waltham facility was released. For the quarter ended March 31, 2022, the Company recorded sublet income totaling $22,795 within operating expenses on the Company's Statement of Operations. Total recorded rent expense was $24,754 and $166,904, for the quarters ended March 31, 2022 and 2021, respectively. The Company records rent expense on its facility leases on a straight-line basis over the lease term. The remaining operating lease term was 3.7 years as of March 31, 2022.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis for the periods presented and indicates the fair value hierarchy of the valuation techniques it utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates, and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. All Company assets and liabilities measured at fair value utilize Level 1 inputs. Fair Value Measurements at March 31, 2022 Using March 31, 2022 Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 20,821,291 $ 20,821,291 $ — $ — Total $ 20,821,291 $ 20,821,291 $ — $ — Fair Value Measurements at December 31, 2021 Using December 31, 2021 Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 20,317,736 $ 20,317,736 $ — $ — Total $ 20,317,736 $ 20,317,736 $ — $ —

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Preferred stock and convertible preferred stock consist of the following: March 31, 2022 December 31, 2021 Preferred stock, $0.001 par value; 5,000,000 shares authorized at March 31, 2022 and December 31, 2021; no shares issued and outstanding at March 31, 2022 and December 31, 2021 $ — $ — Series B convertible preferred stock, $0.001 par value; 147,000 shares designated at March 31, 2022 and December 31, 2021; 200 shares issued and outstanding at March 31, 2022 and December 31, 2021 $ 1 $ 1 2022 equity activity In January 2022, the Company issued 292,500 shares of common stock under its ATM program with net proceeds of $1,943,052 and issued 20,000 restricted stock awards under its 2004 Stock Option Plan with a value of $104,200. As of March 31, 2022, the Company has issued 47,500 restricted stock awards that remain unvested. At December 31, 2021 the Company had 30,000 restricted stock awards that were unvested. Subsequent to March 31, 2022, under its 2004 Stock Option Plan, the Company issued 76,000 restricted stock awards with a value of $326,040 to employees as long term incentives (LTI) and 49,084 shares of fully vested common stock with a value of $210,567 in settlement of management incentive compensation. 2021 equity activity In January 2021, the Company issued 2,408 shares of fully vested common stock with a value of $4,197 pursuant to the Company's 2010 Employee Stock Purchase Plan.

Reverse Stock Split

Reverse Stock Split	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Reverse Stock Split	Stockholders’ Equity Preferred stock and convertible preferred stock consist of the following: March 31, 2022 December 31, 2021 Preferred stock, $0.001 par value; 5,000,000 shares authorized at March 31, 2022 and December 31, 2021; no shares issued and outstanding at March 31, 2022 and December 31, 2021 $ — $ — Series B convertible preferred stock, $0.001 par value; 147,000 shares designated at March 31, 2022 and December 31, 2021; 200 shares issued and outstanding at March 31, 2022 and December 31, 2021 $ 1 $ 1 2022 equity activity In January 2022, the Company issued 292,500 shares of common stock under its ATM program with net proceeds of $1,943,052 and issued 20,000 restricted stock awards under its 2004 Stock Option Plan with a value of $104,200. As of March 31, 2022, the Company has issued 47,500 restricted stock awards that remain unvested. At December 31, 2021 the Company had 30,000 restricted stock awards that were unvested. Subsequent to March 31, 2022, under its 2004 Stock Option Plan, the Company issued 76,000 restricted stock awards with a value of $326,040 to employees as long term incentives (LTI) and 49,084 shares of fully vested common stock with a value of $210,567 in settlement of management incentive compensation. 2021 equity activity In January 2021, the Company issued 2,408 shares of fully vested common stock with a value of $4,197 pursuant to the Company's 2010 Employee Stock Purchase Plan.

Business and Basis of Present_2

Business and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Share-based Payment Arrangement [Policy Text Block]	Stock-based Compensation Total compensation cost related to non-vested awards not yet recognized at March 31, 2022 was $93,991. The total compensation costs are expected to be recognized over a weighted-average period of 3.4 years.
Unaudited Interim Financial Statements	Unaudited Interim Financial Statements The accompanying unaudited balance sheet as of March 31, 2022, unaudited statements of operations, changes in stockholders' equity for the quarters ended March 31, 2022 and 2021 and cash flows for the quarters ended March 31, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying balance sheet as of December 31, 2021 does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair presentation of the Company’s financial position and operating results. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on January 28, 2022 (File No. 001-33351).
Revenues	Revenues Revenues include product sales, net of estimated returns. Revenue is measured as the amount of consideration the Company expects to receive in exchange for product transferred. Revenue is recognized when contractual performance obligations have been satisfied and control of the product has been transferred to the customer. In most cases, the Company has a single product delivery performance obligation. Accrued product returns are estimated based on historical data and evaluation of current information. Accounts receivable are recorded at the amount the Company expects to collect, net of the allowance for doubtful accounts receivable. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses based on customer past payment history, product usage activity, and recent communications with the customer. Individual customer balances which are over 90 days past due are reviewed individually for collectability and written-off when recovery is not probable. Allowance for doubtful accounts was $25,000 as of March 31, 2022 and December 31, 2021.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Quarters Ended March 31, 2022 2021 Net loss applicable to common stockholders $ (958,562) $ (59,783) Weighted average number of common shares outstanding, basic 6,893,164 3,796,120 Weighted average number of common shares outstanding, dilutive 6,893,164 3,796,120 Net loss per common share applicable to common stockholders, basic and diluted $ (0.14) $ (0.02)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Quarters Ended March 31, 2022 2021 Options 510,256 368,510 Convertible preferred stock 62 62 Total 510,318 368,572

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following: March 31, 2022 December 31, 2021 Purchased components $ 413,653 $ 422,093 Finished goods 298,283 284,460 $ 711,936 $ 706,553

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses and compensation consist of the following: March 31, 2022 December 31, 2021 Professional services $ 156,000 $ 109,000 Compensation 825,698 440,474 Warranty 24,800 28,400 Leasehold $ — $ 60,000 Sales Tax $ 139,507 $ 108,788 Other 61,003 67,493 $ 1,207,008 $ 814,155

Leases Leases (Tables)

Leases Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2022 124,339 2023 165,785 2024 165,785 2025 117,431 Total minimum lease payments $ 573,340 Discount rate, 15% $ 141,740 Lease obligation, current portion 148,391 Lease obligation, net of current portion 283,209 $ 573,340

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	Fair Value Measurements at March 31, 2022 Using March 31, 2022 Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 20,821,291 $ 20,821,291 $ — $ — Total $ 20,821,291 $ 20,821,291 $ — $ — Fair Value Measurements at December 31, 2021 Using December 31, 2021 Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 20,317,736 $ 20,317,736 $ — $ — Total $ 20,317,736 $ 20,317,736 $ — $ —

Statement of Shareholders' Equi

Statement of Shareholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Schedule of Stock by Class [Table Text Block]	Preferred stock and convertible preferred stock consist of the following: March 31, 2022 December 31, 2021 Preferred stock, $0.001 par value; 5,000,000 shares authorized at March 31, 2022 and December 31, 2021; no shares issued and outstanding at March 31, 2022 and December 31, 2021 $ — $ — Series B convertible preferred stock, $0.001 par value; 147,000 shares designated at March 31, 2022 and December 31, 2021; 200 shares issued and outstanding at March 31, 2022 and December 31, 2021 $ 1 $ 1

Business and Basis of Present_3

Business and Basis of Presentation (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Organization And Basis Of Presentation [Line Items]
Accounts receivable, net	$ 683,319		$ 310,818
Net proceeds from issuance of stock and warrants	1,943,052	$ 4,197
Accumulated deficit	200,121,819		199,163,257
Cash and cash equivalents	23,769,380		22,572,104
Prepaid expenses and other current assets	(422,616)		(598,384)
Assets, Current	(25,587,251)		(24,187,859)
Accrued Sales Return provisions	11,000		39,000
Liabilities, Current	(1,727,254)		(1,365,697)
Operating Lease, Liability, Noncurrent	(283,209)		(306,709)
Stockholders' Equity Attributable to Parent	24,237,908	5,261,052	23,215,786	$ 5,247,775
Cost of revenues	508,874	576,289
Gross Profit	1,793,517	1,579,183
Compensation cost not yet recognized	$ 93,991
Compensation cost not yet recognized, period for recognition	3 years 4 months 24 days
Operating Lease, Right-of-Use Asset	$ (450,374)		(475,230)
Other long-term assets	(26,400)		(26,400)
Assets	(26,248,371)		(24,888,192)
Accrued Liabilities, Current	(1,207,008)		(814,155)
Liabilities	(2,010,463)		(1,672,406)
Allowance for doubtful accounts	25,000		$ 25,000
Other Comprehensive Income (Loss), Net of Tax	$ 0	$ 0
One Customer | Revenue | Customer Concentration Risk
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage	43.00%	36.00%
Three Customers [Member] | Accounts Receivable | Customer Concentration Risk
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage	55.00%
Two Customers | Accounts Receivable | Customer Concentration Risk
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage			35.00%

Net Loss Per Common Share - Sch

Net Loss Per Common Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	510,318	368,572
Convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	62	62
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	510,256	368,510

Net Loss Per Common Share Sched

Net Loss Per Common Share Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share [Abstract]
Net Income (Loss) Attributable to Parent	$ (958,562)	$ (59,783)
Weighted Average Number of Shares Outstanding, Basic	6,893,164	3,796,120
Weighted Average Number of Shares Outstanding, Diluted	6,893,164	3,796,120
Earnings Per Share, Diluted	$ (0.14)	$ (0.02)
Earnings Per Share, Basic	$ (0.14)	$ (0.02)

Inventories (Detail)

Inventories (Detail) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Inventory [Line Items]
Purchased components	$ 413,653	$ 422,093
Finished goods	298,283	284,460
Inventories	$ 711,936	$ 706,553

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Sales return allowance	$ 11,000	$ 39,000
Accrued Leaseholds Current	0	60,000
Sales and Excise Tax Payable, Current	139,507	108,788
Professional services	156,000	109,000
Warranty reserve	24,800	28,400
Accrued Salaries	825,698	440,474
Other	61,003	67,493
Accrued expenses	$ 1,207,008	$ 814,155

Leases Leases (Details)

Leases Leases (Details) - USD ($)	Jun. 01, 2018	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Operating Leased Assets [Line Items]
Operating Lease, Weighted Average Discount Rate, Percent		15.00%
Operating Lease, Weighted Average Remaining Lease Term		3 years 8 months 12 days
IdleFacilityImpairmentCharge		$ 0	$ 126,748
Operating Lease, Expense		24,754	166,904
Operating Lease, Right-of-Use Asset		450,374		$ 475,230
Sublease Income		22,795
Lessee, Operating Lease, Liability, to be Paid, Year One		124,339
Lessee, Operating Lease, Liability, to be Paid, Year Two		165,785
Lessee, Operating Lease, Liability, to be Paid, Year Three		165,785
Lessee, Operating Lease, Liability, to be Paid, Year Four		117,431
Lessee, Operating Lease, Liability, to be Paid		573,340
Operating Lease Discount		141,740
Operating Lease, Liability, Current		148,391		228,506
Operating Lease, Liability, Noncurrent		283,209		$ 306,709
Woburn Lease [Member]
Operating Leased Assets [Line Items]
Lessee, Operating Lease, Renewal Term	5 years
Woburn Lease [Member] | MonthlyRent [Member]
Operating Leased Assets [Line Items]
Operating Lease, Payments	$ 13,846
Waltham Lease [Member]
Operating Leased Assets [Line Items]
Rent Expense Reduction		$ 60,000
Waltham Lease [Member] | Idle Facility Impairment [Member]
Operating Leased Assets [Line Items]
Restructuring Charges			$ 126,748

Restructuring And Related Activ

Restructuring And Related Activities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Restructuring Cost and Reserve [Line Items]
IdleFacilityImpairmentCharge	$ 0	$ 126,748

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Assets
Cash equivalents	$ 20,821,291	$ 20,317,736
Assets, Fair Value Disclosure	20,821,291	20,317,736
Level 1
Assets
Cash equivalents	20,821,291	20,317,736
Assets, Fair Value Disclosure	20,821,291	20,317,736
Level 2
Assets
Cash equivalents	0	0
Assets, Fair Value Disclosure	0	0
Level 3
Assets
Cash equivalents	0	0
Assets, Fair Value Disclosure	$ 0	$ 0

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended			3 Months Ended
	Apr. 25, 2022	Jan. 31, 2022	Jan. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Class of Stock [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans			2,408
Stock Issued During Period, Value, Employee Stock Purchase Plan			$ 4,197		$ 4,197
Net proceeds from issuance of stock and warrants				$ 1,943,052	$ 4,197
Common stock, par value (in dollars per share)				$ 0.0001		$ 0.0001
Compensation cost not yet recognized				$ 93,991
Compensation cost not yet recognized, period for recognition				3 years 4 months 24 days
Stock Issued During Period, Shares, Restricted Stock Award, Gross		20,000
Stock Issued During Period, Value, Restricted Stock Award, Gross		$ 104,200		$ 0
Stock Issued During Period, Value, New Issues				$ 1,943,052
Subsequent Event [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	76,000
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 326,040
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans					2,408
Stock Issued During Period, Value, Employee Stock Purchase Plan					$ 1
Stock Issued During Period, Shares, New Issues				292,500
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross				1,759
Stock Issued During Period, Value, Restricted Stock Award, Gross				$ 3
Stock Issued During Period, Value, New Issues				$ 29
Management Incentive Compensation | Common Stock [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	49,084
Stock Issued During Period, Value, New Issues	$ 210,567
Restricted Stock
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number				47,500		30,000
At The Market Offering Program [Member] | Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues		292,500
Proceeds from Issuance of Common Stock		$ 1,943,052

Preferred Stock and Convertible

Preferred Stock and Convertible Preferred Stock (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Preferred Non-Convertible Stock
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Value of preferred stock issued	$ 0	$ 0
Preferred stock, shares outstanding (in shares)	0	0
Series B Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	147,000	147,000
Preferred stock, shares issued (in shares)	200	200
Value of preferred stock issued	$ 1	$ 1
Preferred stock, shares outstanding (in shares)	200	200

Reverse Stock Split (Details)

Reverse Stock Split (Details) - shares	Mar. 31, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Shares outstanding (in shares)	7,006,055	6,694,296

Subsequent Event Subsequent Eve

Subsequent Event Subsequent Events (Details) - shares	Mar. 31, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Common Stock, Shares, Issued	7,006,055	6,694,296

Uncategorized Items - nuro-2022

Label	Element	Value
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 22,572,104
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 5,226,213